文献速递白血病

跨大陆成人急性髓系白血病多维分析揭示突变图谱与治疗结局的年龄相关趋势(急性髓系白血病协作组与美国肿瘤临床试验联盟)

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).
PubMed 文献 · Leukemia · 2025-09-19

研究分析美国和德国两个协作组2823例接受一线化疗方案成人AML患者的靶向测序数据,按5岁年龄增量描述基因突变与细胞遗传学频率,并对2756例患者分析分子特征、遗传风险组与年龄相关的临床结局。两队列年龄相关分布相似,总生存随年龄增加几乎线性缩短(P < 0.001),各遗传风险组内生存亦随年龄增加而降低,未发现区分「年轻」与「老年」的年龄切点。

要点

  • 两队列基因突变与细胞遗传学异常的年龄相关分布相似。
  • 全部患者总生存随年龄增加几乎线性缩短(P < 0.001)。
  • 未发现可区分「年轻」与「老年」患者的年龄切点。

核心结论

  • 尽管最年轻与较年长患者的突变图谱和结局不同,但未发现区分「年轻」与「老年」患者的年龄切点。
  • 这些发现支持在药物批准和试验入组方面采取更与年龄相关的灵活性。

研究设计与样本

  • 分析美国和德国两个协作组一线化疗为基础临床方案入组的2823例成人AML患者,采用靶向测序平台进行分子谱分析。
  • 按5岁年龄增量描述基因突变频率和细胞遗传学发现。
  • 对2756例AML患者分析分子特征、遗传风险组和年龄相关的临床结局。

主要发现

  • 两个队列中基因突变和细胞遗传学异常的年龄相关分布相似。
  • 全部患者总生存随年龄增加几乎线性缩短(P < 0.001)。
  • 在2022年欧洲白血病网定义的遗传风险组内,生存随年龄增加而降低(有利风险组 P < 0.001;中等风险组 P < 0.001;不良风险组 P < 0.001)。
  • 最年轻患者的突变图谱和结局与较年长患者不同,但未发现区分「年轻」与「老年」患者的年龄切点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcome of patients with acute myeloid leukemia (AML) worsens with increasing age. Dichotomization into "younger" and "older" patients is clinically routine and often dictates treatment options. We aimed to delineate whether molecular genetic features and/or outcome measures support assorting patient populations by age, including division into "younger" and "older" groups. We analyzed 2823 adult AML patients enrolled onto frontline chemotherapy-based clinical protocols of two cooperative study groups from USA and Germany who were profiled molecularly via targeted sequencing platforms. Frequencies of gene mutations and cytogenetic findings were depicted in 5-year age increments. Clinical outcomes of 2756 AML patients were analyzed with respect to molecular features, genetic-risk groups and age. Age-associated distributions of gene mutations and cytogenetic abnormalities were similar in both cohorts. There was almost linear shortening of overall survival with increasing age among all patients (P < 0.001) and within 2022 European LeukemiaNet-defined genetic-risk groups, with survival decreasing as age increased (favorable-risk, P < 0.001; intermediate-risk, P < 0.001; adverse-risk, P < 0.001). Although mutational profiles and outcomes of the youngest patients differed from those of older patients, there was no age cut-off identifying "younger" and "older" patients. These findings support more age-associated flexibility for drug approval and trial eligibility.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cusan M, Larkin K, Nicolet D, et al. Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology). Leukemia. 2025. PMID: 40973764. doi:10.1038/s41375-025-02644-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。